What is it?

Permanent seed brachytherapy, also known as low dose-rate brachytherapy, involves having tiny radioactive seeds implanted in your prostate gland. Radiation from the seeds destroys cancer cells in the prostate. You may be suitable for this treatment if your cancer is thought to be contained within the prostate gland (localised prostate cancer) and:

If you have a PSA of between 10 and 20, and a Gleason score of 7, this treatment may still be an option for you as long as tests show that the cancer is unlikely to have spread outside of the prostate. Check with your doctor or nurse. It may not be suitable if you have a large prostate gland, severe problems passing urine, or have recently had an operation called a transurethral resection of the prostate (TURP).

You may have this treatment on its own or together with external beam radiotherapy and/or hormone therapy. It is just as good at controlling prostate cancer as other treatments.

There is another type of brachytherapy called temporary brachytherapy or high dose-rate (HDR) brachytherapy. It is less common than permanent seed brachytherapy.

What other treatments are available?

Watch's Chris' story for one man's experience of brachytherapy.

What are the advantages and disadvantages?

What are the advantages and disadvantages?

An advantage for one person might not be for someone else. If you are offered permanent seed brachytherapy, speak to your doctor or nurse before deciding whether to have it. They will be able to help you think about which treatment option is right for you.  There’s usually no rush to make a decision so give yourself time to think about whether permanent seed brachytherapy is right for you.


  • Recovery is quick so most men can return to their normal activities soon after treatment.
  • The radiation is inside the prostate gland and does not travel far, so there may be less damage to the surrounding areas.
  • You will be in hospital for just one or two days for the procedure .
  • If your cancer comes back, you may be able to have further treatment with hormone therapy or cryotherapy – or sometimes surgery although this isn’t common.


  • Permanent seed brachytherapy can cause side effects such as urinary, erection and bowel problems.
  • You will usually need to have a general anaesthetic – which can have side effects.
  • It may be some time before you will know whether the treatment has been successful.
  • You will need to avoid sitting very close to pregnant women or children for more than a few minutes each day, for the first two months after treatment.

What does treatment involve?

You will have a planning session to measure the size and position of your prostate to work out how many radioactive seeds you need. This is also a final check that the treatment is suitable for you. You may have a general anaesthetic so that you are asleep during the procedure, or you could have a spinal or epidural anaesthetic, so that you are awake but cannot feel anything.

The radioactive seeds will either be implanted on the same day as the planning session (one-stage procedure) or they will be implanted two to four weeks later (two-stage procedure). You will have a general anaesthetic or you may have a spinal or epidural anaesthetic. 

Diagram showing brachytherapy seeds inserted into the prostate

You will have a computerised tomography (CT) or magnetic resonance imaging (MRI) scan four to six weeks after the treatment to check the position of the seeds. You will have regular follow-up appointments after this to monitor your PSA level and any side effects. If your treatment has been successful, your PSA level should drop, although it may start to rise again because your prostate will still produce some PSA. Some men may experience a rise and fall in PSA at around one to two years after treatment.


What are the side effects?

You may not have any side effects for several days until the radiation from the seeds begins to take effect. Side effects are generally at their worst a few weeks after treatment, when the radiation dose is strongest, but should then improve over the following months as the seeds lose their radiation.

The most common side effects are:

  • Blood-stained urine or discoloured semen for a few days or weeks.
  • Bruising and pain in the area between your testicles and back passage which can spread to your inner thighs and penis. This will disappear after a week or two.
  • Discomfort when you pass urine and needing to pass urine more often and urgently, especially at night.
  • Problems passing urine, erection problems, bowel problems and tiredness.

Side effects will affect each man differently, and you may not get all of the side effects.

Some men who have had brachytherapy and external beam radiotherapy together may find that they have worse side effects. If you already had urinary, erection or bowel problems before treatment, these may be worse after treatment.

I do have some long term bladder irritability as a result of the radiation, but I manage this with medication.

- A personal experience

Questions to ask your doctor or nurse

  • Will I have a planning session at a different time to the treatment, or immediately before?
  • Will I have external beam radiotherapy or hormone therapy as well as permanent seed brachytherapy?
  • What side effects might I get?
  • How will I know if the treatment has worked?
  • What should my PSA level be after treatment and how often will you measure it?
  • If my PSA continues to rise, what other treatments are available?


  • List of references  

    • Bannuru RR, Dvorak T, Obadan N et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Annals of Internal Medicine 2011; 155 (3): 171-78.
    • Berkley FJ. Managing the adverse effects of radiation therapy. Am Fam Physician 2010;82(4):381–88.
    • Bhatnagar V, Stewart ST, Huynh V et al. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer and Prostatic Diseases 2006; 1-11.
    • Blank TO. Gay men and prostate cancer: invisible diversity. J Clin Oncol 2005;23:2593.
    • British Uro-oncology Group (BUG) & British Association of Urological Surgeons (BAUS) Section of Oncology. Multi-disciplinary team (MDT) guidance for managing prostate cancer. 2013.
    • Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006 Nov 20;24(33):5298-304.
    • Cornell D. A gay urologist’s changing views of prostate cancer. In: Perlman G, Drescher J, editors. A gay man’s guide to prostate cancer. The Haworth Medical Press; Binghamton, NY:2005. p. 29-41.
    • Gaztanga M & Crook J. Interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer. Internation Journal of Urology. 2013;20:142-147
    • Goldstone SE. The ups and downs of gay sex after prostate cancer treatment. In: Perlma G, Drescher J, editors. A Gay Man’s Guide to Prostate Cancer. The Haworth Medical Press;Binghamton, NY: 2005. p. 43-55.
    • Husson O, Mols F & van de Poll-Franse LV. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Annals of Oncology. 2011;22(4):761-72
    • International Commission on Radiological Protection. Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. A report of ICRP Publication 98. Ann ICRP. 2005;35(3):iii-vi, 3-50.
    • Michalski J, Mutic S, Eichling J et al. Radiation exposure to family and household members after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;56(3):764-8.
    • Miller NL & Theodorescu D. Health-related quality of life after prostate brachytherapy. BJU International 2004; 94:487-491.
    • Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012;8:CD008465
    • Miyazawa K, Matoba M, Minato H, Morita N, Chikazawa I, Ota K. Seed migration after transperineal interstitial prostate brachytherapy with I-125 free seeds: analysis of its incidence and risk factors. Jpn J Radiol (2012) 30:635–641
    • Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, et al. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int. J. Radiation Oncology Biol. Phys. 2012;82(1): 204–212.
    • Morton GC, Hoskin PJ.. Brachytherapy: Current Status and Future Strategies. Can High Dose Rate Replace Low Dose Rate and External Beam Radiotherapy? Clinical Oncology. 2013;25:474e482
    • Mottet N, Bastian PJ, Bellmunt J, van der Bergh RCN, Bolla M, van Casteren NJ et al. Guidelines on prostate cancer. European Association of Urology. 2014.
    • Mydlo JH, Lebed B. Does brachytherapy of the prostate affect sperm quality and/or fertility in younger men? Scandinavian Journal of Urology & Nephrology. 2004;38(3):221-4
    • National Institute for Health and Care Excellence. Low dose rate brachytherapy for localised prostate cancer. Interventional Procedure Guidance 132. 2005
    • National Institute for Health and Care Excellence. Prostate cancer: diagnosis and treatment. Clinical guideline. Full guideline. 2014
    • Peinemann F, Grouven U, Bartel C et al. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. European Urology 2011: 60: 881-93.
    • Peinemann F, Grouven U, Hemkens LG et al. Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database of Systematic Reviews 2011, Issue 7. Art No: CD008871.
    • Phan J, Swanson DA, Levy LB et al. Late rectal complications after prostate brachytherapy for localised prostate cancer: incidence and management. Cancer 2009; 115 (9):1827-39.
    • Pillet, S. Don’t Ask, Don’t Tell? The unique needs of GLBT patients with Cancer. ONS Connect. January 2011
    • Price JG, Stone NN, & Stock RG. Predictive factors and management of rectal bleeding side effects following prostate cancer brachytherapy. Internal Journal of Radiation Oncology Biology Physics. 2013;86(5):842-847.
    • Tanaka N, Asakawa I, Anai S, Hirayama A, Hasegawa M, Konishi N. Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy. Radiation Oncology. 201;8:25
    • UK Guidance on Radiation Protection Issues following Permanent Iodine-125 Seed Prostate Brachytherapy. IPEM Report 106. Institute for Physics and Engineering in Medicine. 2012.